Federal investigators subpoena Biogen over MS drug prices

Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy.
In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said it was cooperating with the federal probe, it did not provide any other specific details.
Get the full story at our sister site, Drug Delivery Business News.
The post Federal investigators subpoena Biogen over MS drug prices appeared first on MassDevice.

Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Neurological Pharmaceuticals Wall Street Beat Biogen Source Type: news